Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) rose 8% as the US granted it a crucial reimbursement code, meaning its technology can be used in private and public healthcare programmes.
“We […] view this as an important step towards enhancing accessibility to this innovative technology,” chief executive Christopher von Jako commented.
XENOVIEW, made from a xenon gas blend, is used to increase contrast in MRI scans of patients’ lungs to enable problems to be identified when they breathe.
Polarean is still waiting on details of payment levels though von Jako suggested this would come “in the coming weeks”.
Shares rose 1.25p or 8% to 16.5p.